Bone Biologics Corp Warrants financials
$4.06−5.58%
Close Sep 18, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$3.2M | -$4.2M | -$9.4M | -$3.7M | -$1.1M |
| Net income | -$3.1M | -$7.3M | -$8.9M | -$1.5M | -$1.6M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-2.65 | $-28.96 | $-204.06 | $-186.90 | $-504.00 |
| EBITDA | -$3.2M | -$4.2M | -$9.4M | -$3.7M | -$1.1M |
| Operating cash flow | -$2.7M | -$4.1M | -$9.6M | -$3.6M | -$1.2M |
| Free cash flow | -$2.7M | -$4.1M | -$9.6M | -$3.6M | — |
| Diluted shares | 1.2M | 0.3M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $5.3M | $3.3M | $3.0M | $7.5M | $6.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.8M | $3.9M | $3.7M | $8.5M | $6.7M |
| Total liabilities | $418.6K | $377.7K | $831.4K | $2.5M | $99.9K |
| Shareholders' equity | $5.4M | $3.5M | $2.9M | $5.9M | $6.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology